There is always one drugs trying to stake its place as being better than another. A new report suggests that tiotropium (Spiriva) may be “better” than a rival long-acting bronchodilator, salmetrol (Serevent), in a head-to-head comparison. What the “battle” was about was the length of time to having an exacerbation of COPD related symptoms (cough, sputum production, bronchitis, etc). The tiotropium brand had a longer time to exacerbation (187 days) than the salmetrol (145 days).
One word of caution, however, was ...Continue Reading →